SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.
The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until April 5, 2024.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$24.62 |
| Daily Change: | -1.22 -4.72 |
| Daily Volume: | 1,046,866 |
| Market Cap: | US$4.540B |
June 30, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
